DFRSX
Price
$17.26
Change
-$0.05 (-0.29%)
Updated
Jan 22 closing price
Net Assets
149.05M
FCNSX
Price
$16.03
Change
-$0.00 (-0.00%)
Updated
Jan 22 closing price
Net Assets
5.53B
Ad is loading...

DFRSX vs FCNSX

Header iconDFRSX vs FCNSX Comparison
Open Charts DFRSX vs FCNSXBanner chart's image
DFA Asia Pacific Small Company I
Price$17.26
Change-$0.05 (-0.29%)
VolumeN/A
Net Assets149.05M
Fidelity Series Canada
Price$16.03
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets5.53B
DFRSX vs FCNSX Comparison Chart
Loading...
View a ticker or compare two or three
VS
DFRSX vs. FCNSX commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DFRSX is a Hold and FCNSX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
FCNSX has more cash in the bank: 5.53B vs. DFRSX (149M). DFRSX pays higher dividends than FCNSX: DFRSX (4.60) vs FCNSX (2.45). DFRSX was incepted earlier than FCNSX: DFRSX (32 years) vs FCNSX (7 years). DFRSX (0) and FCNSX (0) have matching initial minimum investment requirements. FCNSX annual gain was more profitable for investors over the last year : 12.66 vs. DFRSX (8.16). FCNSX return over 5 years is better than : 58.56 vs. DFRSX (-3.26).
DFRSXFCNSXDFRSX / FCNSX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence32 years7 years-
Gain YTD3.1682.232142%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets149M5.53B3%
Annual Yield % from dividends4.602.45187%
Returns for 1 year8.1612.6664%
Returns for 3 years-12.6421.43-59%
Returns for 5 years-3.2658.56-6%
Returns for 10 years15.42N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IDR12.270.35
+2.94%
Idaho Strategic Resources
SNX141.500.73
+0.52%
TD SYNNEX Corp
SKYT11.56-0.20
-1.70%
SkyWater Technology
MIRM46.72-1.26
-2.63%
Mirum Pharmaceuticals
PTPI0.31-0.01
-3.31%
Petros Pharmaceuticals